+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasal Drug Delivery Technology Market Analysis Report By Therapeutic Application (Asthma, Rhinitis), By Dosage Form (Powder, Gel, Spray, Drops), By Container Type, And Segment Forecasts, 2019 - 2025

  • ID: 4751816
  • Report
  • January 2019
  • Region: Global
  • 90 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Cadila Pharmaceuticals
  • Douglas NZ
  • GlaxoSmithkline plc.
  • NAVEH Pharma
  • OptiNose
  • MORE
The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR. Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market. According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).

Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine. Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market. Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.

Further key findings from the study suggest:
  • Nasal sprays led the dosage type segment in 2017 due to increased prevalence of asthma and other infectious diseases
  • On the other hand, nasal drops segment witnessed the fastest growth in 2017 owing to availability of cost-effective products with better efficacy
  • Non-pressurized containers segment led the market in 2017 due to continuous development in nasal powders and gel products
  • Asthma was the dominant therapeutic application segment in 2017 and is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast years due to increasing disease prevalence
  • Geographically, North America held the largest share in 2017. Asia Pacific is estimated to witness the fastest CAGR of 7.5% due to presence of key companies, such as Cipla Inc.
  • Some of the leading companies in the global nasal drug delivery technology market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Cadila Pharmaceuticals
  • Douglas NZ
  • GlaxoSmithkline plc.
  • NAVEH Pharma
  • OptiNose
  • MORE
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List of Tables

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation

Chapter 4 Market Definitions

Chapter 5 Industry Outlook
5.1 Market Variable Analysis
5.1.1 Increasing preference for nasal drug delivery technology
5.1.2 Growing incidence of chronic diseases
5.1.3 Growing geriatric population
5.2 Market Restraint Analysis
5.2.1 Complications associated with the overuse of nasal powders

Chapter 6 Business Environment Analysis
6.1 SWOT Analysis; By factor (Political & legal, economic and technological)
6.2 Porter’s Five Forces Analysis

Chapter 7 Dosage Forms Business Analysis
7.1 Nasal Drug Delivery Technology market: Dosage Forms Movement Analysis
7.2 Nasal Spray
7.2.1 Nasal sprays market estimates and forecast, 2014 - 2025
7.3 Nasal Drop
7.3.1 Nasal drops market estimates and forecast, 2014 - 2025
7.4 Nasal Gel
7.4.1 Nasal gels market estimates and forecast, 2014 - 2025
7.5 Nasal Powder
7.5.1 Nasal powder market estimates and forecast, 2014 - 2025

Chapter 8 Container Type Business Analysis
8.1 Nasal Drug Delivery Technology market: Container Type Movement Analysis
8.2 Pressurized container
8.3 Pressurized container market estimates and forecast, 2014 - 2025
8.4 Non-pressurized container
8.5 Non-pressurized container market estimates and forecast, 2014 - 2025

Chapter 9 Therapeutic Application Business Analysis
9.1 Nasal Drug Delivery Technology market: Therapeutic Application Movement Analysis
9.2 Nasal Congestion
9.2.1 Nasal congestion market estimates and forecast, 2014 - 2025
9.3 Rhinitis
9.3.1 Rhinitis market estimates and forecast, 2014 - 2025
9.4 Asthma
9.4.1 Asthma market estimates and forecast, 2014 - 2025
9.5 Others
9.5.1 Others market estimates and forecast, 2014 - 2025

Chapter 10 Regional Business Analysis
10.1 Nasal Drug Delivery Technology Market: Regional Movement Analysis
10.2 North America.
10.2.1 North America market estimates and forecast, 2014 - 2025
10.2.2 U.S.
10.2.2.1 U.S. market estimates and forecast, 2014 - 2025
10.2.3 Canada
10.2.3.1 Canada market estimates and forecast, 2014 - 2025
10.3 Europe
10.3.1 Europe market estimates and forecast, 2014 - 2025
10.3.2 Germany
10.3.3 Germany market estimates and forecast, 2014 - 2025
10.3.4 U.K.
10.3.5 U.K. market estimates and forecast, 2014 - 2025
10.4 Asia-Pacific
10.4.1 Asia-Pacific market estimates and forecast, 2014 - 2025
10.4.2 Japan
10.4.2.1 Japan market estimates and forecast, 2014 - 2025
10.4.3 China
10.4.3.1 China market estimates and forecast, 2014 - 2025
10.4.4 India
10.4.4.1 India market estimates and forecast, 2014 - 2025
10.5 Latin America
10.5.1 Latin America market estimates and forecast, 2014 - 2025
10.5.2 Brazil
10.5.2.1 Brazil market estimates and forecast, 2014 - 2025
10.5.3 Mexico
10.5.3.1 Market estimates and forecast, 2014 - 2025
10.6 Middle East and Africa
10.6.1 Middle-East and Africa market estimates and forecast, 2014 - 2025
10.6.2 South Africa
10.6.3 South Africa market estimates and forecast, 2014 - 2025

Chapter 11 Company Profiles
11.1 Company Profiles
11.1.1 GlaxoSmithkline plc.
11.1.1.1 Company overview
11.1.1.2 Financial Performance
11.1.1.3 Product benchmarking
11.1.1.4 Strategic initiatives
11.1.2 AstraZeneca
11.1.2.1 Company overview
11.1.2.2 Financial performance
11.1.2.3 Product benchmarking
11.1.2.4 Strategic initiatives
11.1.3 Pfizer, Inc.
11.1.3.1 Company overview
11.1.3.2 Financial performance
11.1.3.3 Product benchmarking
11.1.4 OptiNose
11.1.4.1 Company overview
11.1.4.2 Product benchmarking
11.1.4.3 Strategic initiatives
11.1.5 Becton, Dickson and Company
11.1.5.1 Company overview
11.1.5.2 FINANCIAL PERFORMANCE
11.1.5.3 Product benchmarking
11.1.6 Promius Pharma
11.1.6.1 Company overview
11.1.6.2 FINANCIAL PERFORMANCE
11.1.6.3 Product Benchmarking
11.1.6.4 strategic initiatives
11.1.7 B.F. Ascher & Company, Inc.
11.1.7.1 Company overview
11.1.7.2 Product benchmarking
11.1.8 Cadila Pharmaceuticals
11.1.8.1 Company overview
11.1.8.2 Financial performance
11.1.8.3 Product Benchmarking
11.1.9 Douglas NZ
11.1.9.1 Company overview
11.1.9.2 Product benchmarking
11.1.10 ENT Technologies Pty. Ltd.
11.1.10.1 Company Overview
11.1.10.2 Product Benchmarking
11.1.11 Pendopharm
11.1.11.1 Company Overview
11.1.11.2 Product Benchmarking
11.1.12 NAVEH Pharma
11.1.12.1 Company Overview
11.1.12.2 Product Benchmarking
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GlaxoSmithkline plc.
  • AstraZeneca
  • Pfizer, Inc.
  • OptiNose
  • Becton, Dickson and Company
  • Promius Pharma
  • B.F. Ascher & Company, Inc.
  • Cadila Pharmaceuticals
  • Douglas NZ
  • ENT Technologies Pty. Ltd.
  • Pendopharm
  • NAVEH Pharma
Note: Product cover images may vary from those shown
Adroll
adroll